Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Drops By 34.2%

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 29,440 shares, a decrease of 34.2% from the June 30th total of 44,712 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 59,063 shares, the short-interest ratio is presently 0.5 days.

Barinthus Biotherapeutics Trading Up 4.7%

Shares of BRNS traded up $0.03 during mid-day trading on Friday, hitting $0.58. The company’s stock had a trading volume of 26,383 shares, compared to its average volume of 42,098. Barinthus Biotherapeutics has a 1-year low of $0.51 and a 1-year high of $1.83. The firm has a market capitalization of $23.81 million, a P/E ratio of -0.45 and a beta of -0.41. The firm has a 50-day simple moving average of $0.66 and a 200 day simple moving average of $0.65.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.14.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.00.

Institutional Investors Weigh In On Barinthus Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Barinthus Biotherapeutics by 115.8% during the 4th quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after purchasing an additional 76,800 shares during the period. Rangeley Capital LLC increased its holdings in shares of Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares in the last quarter. Finally, Baird Financial Group Inc. lifted its stake in shares of Barinthus Biotherapeutics by 108.2% in the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock valued at $179,000 after purchasing an additional 100,000 shares during the period. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.